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Purpose: To determine the optimal doses of the antiepidermal
growth factor receptor (anti-EGFR) monoclonal antibody cetuximab
and the EGFR tyrosine kinase inhibitor gefitinib when administered
as a combination for patients with advanced/metastatic non-small
cell lung cancer (NSCLC) previously treated with platinum-based
chemotherapy.
Patients and Methods: Patients with advanced/metastatic NSCLC
treated with prior platinum-based chemotherapy received escalating
doses of weekly cetuximab (100, 200, and 250 mg/m2, IV) and fixed
doses of gefitinib (250 mg/d, PO) until disease progression or
unacceptable toxicity. Available tumor samples were analyzed for
EGFR expression, EGFR gene copy number and mutations, and
K-RAS mutations.
Results: Thirteen patients were enrolled in three cohorts. Treatment
was generally well-tolerated at all doses. One grade 3 headache,
observed on the first treatment cycle was initially considered dose-
limiting toxicity (DLT); this event was eventually determined to be
caused by a brain metastasis, not toxicity. Three cases of grade 3/4
hypomagnesemia and 1 case of grade 3 skin rash occurred in the
highest-dose cohort. Grade 1/2 infusion reactions occurred in three
patients without requiring treatment discontinuation. Four patients
(31%) achieved stable disease, no responses were observed. None of
the patients had EGFR mutations or gene amplification in their
tumor samples.
Conclusion: Dual EGFR inhibition with cetuximab and gefitinib is
feasible; the combination can be safely administered and may have
modest activity in advanced/metastatic NSCLC. Cetuximab 250
mg/m2 weekly IV and gefitinib 250 mg/d PO is the recommended
phase II dose, although the potential for late-onset hypomagnesemia
warrants close monitoring of patients receiving this combined dosage.
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Cancer of the lung and bronchus remains the leading causeof cancer death among men and women in the United
States.1,2 Platinum-based combinations are the cornerstone of
front-line therapy for patients with advanced/metastatic dis-
ease, and several agents are available (such as docetaxel and
pemetrexed) after failure of initial platinum-based chemo-
therapy. Despite the continued development of novel thera-
pies, response rates typically remain less than 10% for sec-
ond-line regimens.2–4
Inhibition of the epidermal growth factor receptor
(EGFR) has emerged as a valid therapeutic strategy for the
treatment of advanced/metastatic non-small cell lung cancer
(NSCLC). EGFR is expressed in several solid malignancies,
including NSCLC,5–7 and abnormal EGFR activity is known
to contribute to numerous tumorigenic processes.8 Currently,
two approaches to EGFR inhibition are available: (1) targeted
monoclonal antibodies that prevent the binding of ligands to
EGFR, and (2) small molecule tyrosine kinase inhibitors
(TKIs) that block the intracellular catalytic activity of the
receptor.7
The chimeric IgG1 mAb cetuximab (ERBITUX, Im-
Clone Systems Incorporated, New York, NY, and Bristol-
Myers Squibb Company, Princeton, NJ) is the most compre-
hensively studied anti-EGFR- antibody. By blocking the
ligand-receptor interaction, cetuximab down-regulates EGFR
signaling and subsequently inhibits cell proliferation, induces
apoptosis and reduces angiogenesis.6,7,9 In vitro studies also
show that cetuximab may mediate antibody-dependent cellu-
lar cytotoxicity.10,11 Cetuximab in combination with chemo-
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therapy has been approved by the FDA for the treatment of
metastatic colorectal cancer (CRC) and with radiotherapy for
the treatment of locally advanced head and neck cancer
(HNC).12–15 Cetuximab has also demonstrated activity as a
single agent as well as in combination with docetaxel in patients
with advanced, chemotherapy-refractory NSCLC.16,17 In first-
line advanced/metastatic NSCLC, several phase II trials have
shown that cetuximab in combination with platinum-based che-
motherapy is well-tolerated and has promising activity.18–21
Among the receptor TKIs, single-agent erlotinib
(Tarceva, Genentech, Inc, South San Francisco, CA, and OSI
Pharmaceuticals Inc., Melville, NY) improves survival in
advanced NSCLC patients who progressed after one or two
prior chemotherapy regimens.2,22 Although gefitinib (Iressa,
AstraZeneca, Wilmington, DE), another EGFR TKI, has also
demonstrated antitumor activity in this setting, overall sur-
vival benefit was not noted in a phase III trial that compared
it to placebo, except in certain subsets (nonsmokers and
patients of Asian origin).23
A series of biologic factors may determine response or
resistance to EGFR inhibitors in NSCLC. Somatic mutations
in the EGFR gene have been identified as predictors of
clinical response to TKIs.24–26 However, in a phase III trial
of chemotherapy with or without erlotinib, the presence of
EGFR mutations was also associated with improved survival
irrespective of treatment.27 High EGFR expression and high
EGFR gene copy number have both been shown to signifi-
cantly correlate with survival in patients treated with EGFR
TKIs,28 whereas the presence of markers related to down-
stream events, such as K-Ras and Akt signaling, seems to
predict resistance to therapy.27,29–31
By combining anti-EGFR monoclonal antibodies and
TKIs, it may be possible to achieve simultaneous vertical
inhibition of EGFR and enhance abrogation of downstream
activity. Residual EGFR activity after exposure to either class
of inhibitor alone may allow cancer cells to remain viable, but
simultaneous dual inhibition may cause apoptosis.32 Results
in xenograft models support this hypothesis: a synergistic
effect has been observed when cetuximab is administered in
combination with erlotinib or gefitinib compared with treat-
ment with either agent alone.33,34 Cetuximab has been shown
to down-regulate EGFR on the cellular surface, potentially
enhancing the sensitivity to TKIs. The combination of cetux-
imab plus erlotinib seems synergistic in terms of apoptotic
activity in vitro, and results in additive tumor growth inhibi-
tion in vivo.32,33
This phase I study was designed to determine the
optimal dosing of cetuximab and gefitinib that can be safely
administered in combination to patients with advanced
NSCLC that had been treated with one or two prior chemo-
therapy regimens.
PATIENTS AND METHODS
Eligibility Criteria
Patients with histologically or cytologically confirmed
advanced/metastatic NSCLC were eligible. Other inclusion
criteria: age 18 years; at least one prior platinum-based
chemotherapy regimen; ECOG performance status 0 to 1 and
a life expectancy of 3 months; one bidimensionally mea-
surable lesion, and adequate bone marrow, renal, and hepatic
function. Patients with prior anti-EGFR therapy or with
history of prior hypersensitivity to chimerized or murine
antibodies were ineligible.
This study was performed after approval by a local
Human Investigations Committee and in accord with an
assurance filed with and approved by the Department of
Health and Human Services where appropriate. Informed
consent was obtained from each participant.
Trial Design
This was an open-label, uncontrolled, interventional,
phase I, dose-escalation trial. Treatment consisted of escalat-
ing doses of cetuximab (100, 200, 250 mg/m2/wk IV) without
initial loading dose and gefitinib at a fixed daily dose (250 mg
orally) until disease progression or unacceptable toxicity.
The primary end point of the study was to determine the
recommended phase II dose (RPTD) of the combination
regimen. The secondary endpoints were safety (including
determination of maximum tolerated dose [MTD], and rates
of adverse events (AEs) and abnormal laboratory parame-
ters), and efficacy (including response rates). Analyses of
EGFR expression, EGFR mutation status, and EGFR gene
copy number, were included as tertiary endpoints.
An accelerated titration design was used. Dose escala-
tion proceeded with one patient/cohort until the first DLT or
a second instance of grade 2 toxicity during the first treatment
cycle (4 weeks). Thereafter, three to six patients were en-
rolled to each dosing level. The MTD was defined as the
highest dose at which fewer than two of six subjects experi-
ence a DLT. Dose escalation was halted at the recommended
monotherapy doses of cetuximab and gefitinib (250 mg/m2
and 250 mg/d, respectively), which would be considered the
RPTD if the MTD was not reached.35
DLT was defined as the occurrence of 1 of the
following events during the first treatment cycle: any grade 4
infusion reaction; any grade 3 skin toxicity requiring inter-
ruption of any agent for 14 days; nonhematologic toxicity
grade 3; any grade toxicity (other than skin toxicity) re-
quiring removal from study or the withholding of retreatment
for 4 weeks; grade 4 neutropenia for 5 days; grade 3/4
neutropenia with sepsis or a fever 38.5°C (oral), any dura-
tion; thrombocytopenia of 25,000 platelets/mm3 (or bleed-
ing requiring a platelet infusion).
Dose modifications for gefitinib were not allowed.
Cetuximab dose was reduced in the event of toxicity, re-
escalation was not permitted. Doses that could not be admin-
istered on time were omitted. In case of infusion reaction,
cetuximab dose was modified after United States Package
Insert recommendations. In the event of grade 3 rash, cetux-
imab and gefitinib were discontinued for 1 to 2 weeks until
improvement, and reinstated at the same dose level. Recurrence
of grade 3 rash required cetuximab dose reduction, but a
fourth occurrence required discontinuation; gefitinib treatment
could continue. Any rash that did not improve within 1 to 2
weeks required total treatment discontinuation.
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Response and Toxicity Evaluation Criteria
Baseline laboratory evaluations were performed within 14
days of the first dose. Response was assessed by investigator and
sponsor using imaging studies; tumor measurements were per-
formed q8 weeks (more frequently when indicated). Responses
to therapy required 4-week confirmation.
AEs were evaluated by worst severity per subject (ac-
cording to the National Cancer Institute Common Terminol-
ogy Criteria for Adverse Events [NCI-CTCAE v 3.0]), using
the most current version of the Medical Dictionary for Reg-
ulatory Activities (MedDRA v 9.1). Laboratory tests not
evaluable using NCI-CTCAE v 3.0 criteria were summarized
as below, within or above normal limits.
Acneform rash was a composite term defined as any
rash, rash pustular, rash erythematous, dermatitis acneform,
dermatitis exfoliative, rash papular, rash pruritic, rash gener-
alized, rash maculo-papular, acne, acne pustular, skin des-
quamation, and dry skin event. Infusion reaction, also a
composite term, was characterized as any allergic reaction or
anaphylactoid reaction during study, or any allergic reaction,
anaphylactoid reaction, fever, chills, chills and fever, or
dyspnea event occurring on the first day of dosing.
DNA Sequencing, EGFR Gene Copy Number,
and EGFR Protein Expression Analysis
DNA sequencing, gene copy number, and immunohis-
tochemistry analyses were conducted in formalin-fixed, par-
affin-embedded (FFPE) tumor tissue samples obtained from
patients with 1 therapy dose and sufficient pretreatment
samples available.
Gene copy number analysis was performed using the
TaqMan (Applied Biosystems, Foster City, CA) assay.14
Exons 18, 19, 20, and 21 of EGFR and exon 2 of K-RAS were
sequenced using dye-terminator chemistry on PCR samples
purified by solid-phase reversible immobilization.36,37 Reac-
tion products were analyzed by capillary electrophoresis in a
PRISM 3730  DNA analyzer (Applied Biosystems), and
sequences were analyzed with PolyPhred software.38
FFPE tumor samples were submitted to QualTek (New-
town, PA) for EGFR expression analysis by immunohisto-
chemistry. The intensity of staining was scored as: 3  high,
2  moderate, 1  low/minimal, and 0  no staining.
RESULTS
Patient Demographics
Between March 2005 and February 2006, 13 patients
were screened and enrolled into three cohorts. One patient
was enrolled into the lowest treatment dose cohort (100
mg/m2), and six patients each were enrolled in the 200 mg/m2
and 250 mg/m2 cohorts (Figure 1). Baseline characteristics of
the 13 treated patients are listed in Table 1. The median age
was 63 years (range, 51–77 years). Nine patients (69%) were
men, and all patients enrolled were Caucasian. Seven patients
(54%) had an ECOG performance status of 0, and the re-
maining six had a PS of 1. Adenocarcinoma was the most
Cohort 1 
100 mg/m2 cetuximab + 
250 mg/m2 gefitinib 
Initial n = 1 
No DLTs observed 
No additional accrual 
n = 1 
     
Cohort 2 
200 mg/m2 cetuximab + 
250 mg/m2 gefitinib 
Initial n = 1 
DLTs observed 
• Gr. 3 headache* 
Cohort expanded 
n = 6 
     
Cohort 2 
250 mg/m2 cetuximab + 
250 mg/m2 gefitinib 
Initial n = 1 
DLTs observed  
in prior cohort 
Cohort expanded 
n = 6 
Abbreviation: DLT, dose-limiting toxicity.  
* This event was eventually determined to be related to a brain metastasis. 
FIGURE 1. Recruitment schema. DLT,
dose-limiting toxicity. *This event was
eventually determined to be related to a
brain metastasis.
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common histology (10 patients). One patient had adenocar-
cinoma with bronchioloalveolar features and three patients
had a squamous histology. Eight (61.5%) patients had re-
ceived one prior chemotherapy regimen, with the remaining
five receiving two prior regimens.
Treatment Exposure
Treatment with cetuximab plus gefitinib was feasible
across all dose cohorts, with eight patients discontinuing treat-
ment because of disease progression and four patients because
of AEs. One patient was lost to follow-up.
In the lowest cetuximab dose cohort (100 mg/m2), the
patient was treated for 7.1 weeks with cetuximab, and 7.3
weeks with gefitinib. A total of seven infusions of cetuximab
(one omitted) and 49 doses of gefitinib (five omitted) were
administered.
In the 200 mg/m2 cohort (n  6), the median duration
of treatment for cetuximab was 12.0 weeks (range, 1.0–36.7),
and for gefitinib was 11.5 weeks (range, 0.3–36.7). Patients in
this cohort received a total of 85 infusions of cetuximab (11
omitted). One infusion of cetuximab was administered at a
reduced dose, and a second full dose was infused at a reduced
rate. One patient required an interruption of cetuximab infu-
sion. A total of 547 doses of gefitinib were administered (54
omitted).
The median duration of treatment in the 250 mg/m2
cohort (n  6) was 7.9 weeks (range, 4.0–9.1) for cetuximab
and 7.8 weeks (range, 4.9–8.0) for gefitinib. Forty-two infu-
sions of cetuximab were administered (10 omitted), one
infusion administered at a reduced dose, and one reported
interruption of cetuximab infusion. Patients in this cohort
received 287 doses of gefitinib (30 omitted).
Adverse Events
All 13 patients were evaluable for toxicity (Table 2).
Cetuximab in combination with gefitinib was generally well-
tolerated, and safety profiles were similar across treatment
cohorts. The most common AE related to treatment was
acneform rash, reported in 11/13 patients (84.6%). Although
all patients enrolled in the 250 mg/m2 cohort experienced
skin toxicities, only one patient (7.7%) presented with a grade
3 rash that required discontinuation from further study ther-
apy. Additional grade 3/4 drug-related AEs were infrequent
across all treatment cohorts except for hypomagnesemia.
The patient in the 100 mg/m2 cohort had grade 3 fatigue,
and one patient in the 200 mg/m2 cohort experienced grade 3
diarrhea (16.7%). One patient in the 200 mg/m2 cohort
experienced a grade 3 headache initially regarded as a DLT;
although subsequent evaluation determined this event to be
related to a brain metastasis, this cohort was expanded to a
total of six patients regardless. No other episodes of DLT
were noted in either the expanded 200 mg/m2 cohort, or in six
patients treated at the 250 mg/m2 dose of cetuximab. Grade
3/4 hypomagnesemia was not observed in the lower dose
cohorts (100 and 200 mg/m2), but was reported in 3/6 patients
(50%) in the highest dose cohort (250 mg/m2), requiring
discontinuation of therapy in two patients.
Two grade 2 infusion reactions were reported in two
patients in the 200 mg/m2 cohort and one patient (grade 1) in
TABLE 1. Patient Characteristics (N  13)
No. of
Patients Percent
Age, yr
Median 63
Range 51–77
65 6 46.2
Dose cohort
100 mg/m2 cetuximab  250 mg/m2 gefitinib 1 7.7
200 mg/m2 cetuximab  250 mg/m2 gefitinib 6 46.2
250 mg/m2 cetuximab  250 mg/m2 gefitinib 6 46.2
Gender
Male 9 69.2
Female 4 30.8
ECOG performance status
0 7 53.8
1 6 46.2
Smoking history
Never smoked 1 7.7
Former smokers 10 76.9
Current smokers 2 15.4
Histology
Adenocarcinoma 10 76.9
Adenocarcinoma with BAC features 1 7.7
Squamous cell carcinoma 3 23.1
Prior surgery 10 76.9
Prior radiotherapy 9 69.2
Prior chemotherapy regimens
1 8 61.5
2 5 38.5
Prior chemotherapy drugs for NSCLC
Carboplatin 11 84.6
Cisplatin 3 23.1
Docetaxel 7 53.8
Gemcitabine 2 15.4
Paclitaxel 10 76.9
Baseline hematology (WBC)
Grade 0 11 84.6
Grade 1 2 15.4
Baseline hematology (ANC)
Grade 0 11 84.6
Grade 1 1 7.7
Grade 2 1 7.7
Platelets (low)
Grade 0 11 84.6
Grade 1 2 15.4
Hemoglobin (low)
Grade 0 7 53.8
Grade 1 5 38.5
Grade 2 1 7.7
Magnesium (low)
Grade 0 7 53.8
Grade 1 3 23.1
Not reported 3 23.1
ECOG, Eastern Cooperative Oncology Group; BAC, bronchioloalveolar carci-
noma; NSCLC, non-small cell lung cancer; WBC, white blood cell count; ANC,
absolute neutrophil count.
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the 250 mg/m2 cohorts, respectively. However, these reac-
tions did not require interruption of cetuximab therapy.
Based on the incidence of DLTs occurring in the first
cycle of treatment, cetuximab dose could be escalated to the
highest level and the RPTDwas determined to be cetuximab 250
mg/m2 weekly IV in combination with gefitinib 250 mg/d PO.
Efficacy and Molecular Studies
Thirteen patients were available for efficacy analysis.
Although responses were not observed, stable disease was
achieved in four patients, for a disease control rate of 31%.
Eight patients had progressive disease and one patient was
not evaluable for response.
FFPE tumor samples were obtained from 10 patients.
Samples were analyzed to determine EGFR gene copy num-
ber as well as for presence of mutations in EGFR and K-RAS.
Quantitative PCR analysis performed to determine the gene
copy number of EGFR relative to that of a control gene
(VEST1) did not detect increases in EGFR gene copy number
among all patients evaluable for efficacy. No mutations were
found in K-RAS (exon 2) or the EGFR kinase domain (exons
18, 19, 20, and 21) in any of the samples.
Immunohistochemical analysis for EGFR expression
showed similar levels throughout the five samples evaluated,
with a score of 3 regardless of response.
DISCUSSION
This is the first study conducted specifically in ad-
vanced/metastatic NSCLC patients that evaluated the combi-
nation of an EGFR monoclonal antibody, cetuximab, and a
TKI, gefitinib. The study demonstrated that combination of
cetuximab and gefitinib is a feasible and tolerable treatment
strategy in this patient population. The safety profile for the
combination was consistent with the individual safety profile
of each drug and no unexpected toxicities occurred. The
RPTD was determined to be the highest dose in this study,
cetuximab 250 mg/m2 weekly IV and gefitinib 250 mg/d PO.
These safety findings contrast with another phase I
study in advanced solid tumors, in which escalating doses of
erlotinib were combined with fixed doses of cetuximab and
bevacizumab. Rash, diarrhea, and hypomagnesemia were
reported as DLTs and the dose of erlotinib in combination
with standard weekly dosages of cetuximab had to be re-
duced, from 100 to 50 mg/d PO, before the addition of
bevacizumab.39 In the current trial, skin toxicities and diar-
rhea were not found to be dose-limiting. Only one patient
experienced grade 3 rash associated with cetuximab and three
patients at the highest dose level developed low-grade 1
diarrhea manageable with supportive therapy.
An interesting observation in this study, however, is the
occurrence of severe hypomagnesemia after the first treat-
ment cycle. Three patients at the highest dose level (eventu-
ally recommended as phase II dose) experienced grade 3/4
hypomagnesemia, and two of them had to discontinue treat-
ment. It is possible that these toxicities may account for the
shorter median duration of treatment for the 250 mg/m2
cohort compared with the 200 mg/m2 cohort, which had only
one treatment discontinuation due to toxicity. Because the
development of grade 3/4 hypomagnesemia at the highest
dose level did not occur during the initial treatment cycle,
these events were not DLTs according to protocol. However,
the relatively high incidence of this toxicity in the 250 mg/m2
cohort, compared with the lower-dose cohorts, underscores
the need for close monitoring of patients treated at the
recommended combination dose. Another phase I study in-
vestigating the feasibility of cetuximab plus gefitinib (esca-
lating doses for both agents),40 also found severe toxicities
beyond the protocol-defined period for DLTs. Hypomag-
nesemia, however, was not among the toxicities described as
late DLTs. Moreover, higher doses of both cetuximab and
gefitinib were reached (up to gefitinib 500 mg/d PO plus
cetuximab 400 mg/m2 followed by 250 mg/m2 weekly) than
in this study, which is reassuring of both the overall feasibil-
ity of the combination and the tolerability of the phase-II dose
recommended here.
In the current trial, genetic analysis did not detect
increases in EGFR gene copy number or mutations in EGFR
or K-RAS in any of the patients, although these results are of
limited value, given the small sample number. A modest level
of antitumor activity was observed, with stable disease in
4/13 evaluable patients (31%). Baselga and colleagues have
reported promising activity in patients with advanced solid
tumors with cetuximab plus gefitinib. In their study, patients
with advanced CRC (n  24), HNC (n  17), or NSCLC
(n  2) were administered weekly cetuximab and daily
gefitinib as single agents or in combination. One patient
receiving single agent cetuximab achieved a partial response,
and seven responses were reported in the cetuximab/gefitinib
cohorts (28% Objective Response Rate), including one HNC
patient achieving a complete response. In the subset of
patients with CRC receiving the combination, the response
TABLE 2. Adverse Eventsa (N  13)
% of Patients
Any Grade Grade 3/4
Rash 11 (84.6) 1 (7.7)
Gastrointestinal toxicity 9 (69.2) 1 (7.7)
Diarrhea 5 (38.5) 1 (7.7)
Nausea 4 (30.8) 0
Constipation 3 (23.1) 0
Vomiting 1 (7.7) 0
Metabolism/nutrition disorders 7 (53.9) 3 (23.1)
Anorexia 4 (30.8) 0
Decreased appetite 2 (15.4) 0
Hypomagnesemia 3 (23.1) 3 (23.1)
Fatigue 8 (61.5) 1 (7.7)
Infusion reaction 3 (23.1) 0
Weight loss 2 (15.4) 0
Back pain 1 (7.7) 0
Headache 2 (15.4) 1 (7.7)
Peripheral neuropathy 1 (7.7) 0
Confusion 1 (7.7) 0
Cough 1 (7.7) 0
a Shown as worst grade drug-related toxicity per patient.
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rate was higher (56%, all PRs). Pharmacodynamic analysis
demonstrated significantly superior inhibition of EGFR,
MAPK, and Akt phosphorylation, decreased tumor cell pro-
liferation and increased apoptosis in biopsies of patients
receiving the cetuximab/gefitinib combination, over those
treated with either agent alone (p  0.05), indicating that a
combination of anti-EGFR agents may inhibit of EGFR
activity and downstream signaling more potently.40
The difference in efficacy observed across these clinical
studies has not been comprehensively studied, but it is likely
because of the small number of patients in this study as well
as different tumor types (all NSCLC patients versus a major-
ity of patients with metastatic CRC).
In conclusion, this study demonstrated that treatment
with cetuximab plus gefitinib is feasible in patients with
recurrent NSCLC, and identified a recommendable combina-
tion dose for phase II evaluation. Albeit not conclusive due to
the small number of samples analyzed, it is noteworthy that
the four patients experiencing disease stabilization (best re-
sponse in this study) had no EGFR mutations or an increase
in EGFR gene copy number. Thus, this regimen warrants
further investigation, and future disease-specific phase II
studies could provide insight on its profile by incorporating
genetic and biomarker analyses.
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